ProCE Banner Activity

Primary Analysis of ZUMA-7: Randomized Phase III Trial of 2L Axicabtagene Ciloleucel vs Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma

Slideset Download
Conference Coverage
ZUMA-7 met the primary endpoint demonstrating a >4-fold improvement in EFS with axicabtagene ciloleucel vs standard of care.

Released: December 13, 2021

Expiration: December 12, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation